StockData
Lisata Therapeutics, Inc. logo

Lisata Therapeutics, Inc. (LSTA) stock

LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.04−0.05 (-4.59%)

Close on Nov 17, 2026Market cap $9.37MP/E –Yield –

Lisata Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lisata Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$16.43M. For fiscal 2025 it was -$18.21M. The highest annual figure on record is -$16.99M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.21M–
FY2024Dec 31, 2024-$22.41M–
FY2023Dec 31, 2023-$25.71M–
FY2022Dec 31, 2022-$57.60M–
FY2021Dec 31, 2021-$29.05M–
FY2020Dec 31, 2020-$19.15M–
FY2019Dec 31, 2019-$20.09M–
FY2018Dec 31, 2018-$16.99M–
FY2017Dec 31, 2017-$27.59M–
FY2016Dec 31, 2016-$29.50M–
FY2015Dec 31, 2015-$113.85M–
FY2014Dec 31, 2014-$57.74M–
FY2013Dec 31, 2013-$36.81M–
FY2012Dec 31, 2012-$30.39M–
FY2011Dec 31, 2011-$34.00M–
FY2010Dec 31, 2010-$18.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.99M–
Q1 FY2026Mar 31, 2026-$4.94M–
Q4 FY2025Dec 31, 2025-$3.08M–
Q3 FY2025Sep 30, 2025-$4.41M–
Q2 FY2025Jun 30, 2025-$4.87M–
Q1 FY2025Mar 31, 2025-$5.85M–
Q4 FY2024Dec 31, 2024-$4.95M–
Q3 FY2024Sep 30, 2024-$5.34M–
Q2 FY2024Jun 30, 2024-$5.52M–
Q1 FY2024Mar 31, 2024-$6.60M–
Q4 FY2023Dec 31, 2023-$6.03M–
Q3 FY2023Sep 30, 2023-$5.96M–
Q2 FY2023Jun 30, 2023-$6.88M–
Q1 FY2023Mar 31, 2023-$6.84M–
Q4 FY2022Dec 31, 2022-$6.54M–
Q3 FY2022Sep 30, 2022-$37.72M–
Q2 FY2022Jun 30, 2022-$6.72M–
Q1 FY2022Mar 31, 2022-$6.62M–
Q4 FY2021Dec 31, 2021-$6.85M–
Q3 FY2021Sep 30, 2021-$6.97M–
Q2 FY2021Jun 30, 2021-$7.15M–
Q1 FY2021Mar 31, 2021-$8.09M–
Q4 FY2020Dec 31, 2020-$5.45M–
Q3 FY2020Sep 30, 2020-$5.35M–
Q2 FY2020Jun 30, 2020-$4.29M–
Q1 FY2020Mar 31, 2020-$4.06M–
Q4 FY2019Dec 31, 2019-$5.08M–
Q3 FY2019Sep 30, 2019-$5.07M–
Q2 FY2019Jun 30, 2019-$5.35M–
Q1 FY2019Mar 31, 2019-$4.59M–
Q4 FY2018Dec 31, 2018-$3.80M–
Q3 FY2018Sep 30, 2018-$3.76M–
Q2 FY2018Jun 30, 2018-$4.27M–
Q1 FY2018Mar 31, 2018-$5.16M–
Q4 FY2017Dec 31, 2017-$7.32M–
Q3 FY2017Sep 30, 2017-$6.13M–
Q2 FY2017Jun 30, 2017-$7.71M–
Q1 FY2017Mar 31, 2017-$6.43M–
Q4 FY2016Dec 31, 2016-$5.49M–
Q3 FY2016Sep 30, 2016-$5.73M–

More Lisata Therapeutics figures

See a number that looks wrong?